Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 3/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | TK2 | O00142 | 1/20 | 0.56 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.54 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | BLM | P54132 | 1/20 | 0.52 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8925580 | 0.93 | TK1 (0.59) | TK1LMNASMN1; SMN2TK2ALOX12 | |
| SCHEMBL8925599 | 0.93 | TK1 (0.59) | TK1LMNASMN1; SMN2TK2ALOX12 | |
| SCHEMBL13222053 | 0.93 | LMNA (0.58) | TK1LMNASMN1; SMN2TK2ALOX12 | |
| SCHEMBL29757418 | 0.91 | TK1 (0.58) | TK1LMNASMN1; SMN2TK2ALOX12 | |
| SCHEMBL25469567 | 0.91 | TYMS (0.47) | — | |
| SCHEMBL25470064 | 0.91 | TYMS (0.47) | — | |
| SCHEMBL8926757 | 0.90 | TK1 (0.52) | TK1LMNASMN1; SMN2TK2ALOX12 | |
| SCHEMBL8926762 | 0.90 | TK1 (0.52) | TK1LMNASMN1; SMN2TK2ALOX12 | |
| SCHEMBL15115328 | 0.89 | TK1 (0.52) | TK1LMNASMN1; SMN2TK2ALOX12 | |
| SCHEMBL18214117 | 0.88 | LMNA (0.59) | TK1LMNASMN1; SMN2TK2ALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11655502-B2 | Short pendant arm linkers for nucleotides in sequencing applications | ILLUMINA CAMBRIDGE LIMITED (GB) | 2023-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11655502-B2 | Short pendant arm linkers for nucleotides in sequencing applications | POLRMT, POLM, POLN | TK1 257/4885LMNA 1346/4885SMN1; SMN2 1016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.